



Early Clinical Development Studies Experience

	Lp.	Indication	Active substance	Phase	Route of administration
Early Phases	1	Healty Subjects	SB-681323	Phase I	Oral / Tablets
	2	Healty Subjects	Dimethylfumarate, Ethylhydrogenfumarate, calcium salt, Ethylhydrogenfumarate, magnesium salt, Ethylhydrogenfumarate, zinc salt	Phase I	Oral / Tablets
	3	Impaired Hepatic Function	Dapagliflozin	Phase I	Oral / Tablets
	4	Cancer pain	Fentanyl	Phase I	Oral / Tablets
	5	Healty Subjects	Dimethylfumarate, Ethylhydrogenfumarate, calcium salt, Ethylhydrogenfumarate, magnesium salt, Ethylhydrogenfumarate, zinc salt	Phase I	Oral / Tablets
	6	Impaired Hepatic Function	Bupivacaine	Phase I	Subcutaneous
	7	Healty Subjects	JNJ-31001074	Phase I	Oral / Tablets
	8	Impaired Hepatic Function	Semagacestat	Phase I	Oral / Tablets
	9	Metastatic Solid Tumors	Tasisulam (LY573636)	Phase I	Oral / Tablets
	10	Hemophilia B	IB1001	Phase I	Intravenous
	11	Healty Subjects	Escitalopram, TMC435	Phase I	Oral / Tablets
	12	Impaired Hepatic Function	LY2624803	Phase I	Oral / Tablets
	13	Peritoneal cancer	Albendazole	Phase I	Oral / Tablets
	14	Healty Subjects	Etravirine (ETR); Darunavir (DRV); artemether/lumefantrine	Phase I	Oral / Tablets
	15	Rheumatoid arthritis	Rituximab	Phase I	Intravenous
	16	Atopic Dermatitis	REGN846	Phase I	Intravenous
	17	Plaque Psoriasis	Genistein	Phase I	Oral
	18	Healty Subjects	Ropivacaine	Phase I	Subcutaneous
	19	Impaired Hepatic Function	Midostaurin	Phase I	Oral
	20	Healty Subjects	Apomorphine hydrochloride	Phase I	Subcutaneous
	21	Mantle Cell Lymphoma	Acalabrutinib	Phase I	Oral / Capsule
	22	Rheumatoid arthritis	MEDI4736	Phase I	Intravenous
	23	Non-Hodgkin Lymphoma	AFM11	Phase I	Intravenous

Date issue: June 2018

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



21230869/3/Q

Early Clinical Development Studies Experience

	Lp.	Indication	Active substance	Phase	Route of administration
Early Phases	24	Healty Subjects	Adalimumab	Phase I	Subcutaneous
	25	Healty Subjects	Sulthiame	Phase I	Oral / Tablets
	26	Healty Subjects	Sulthiame	Phase I	Oral
	27	Healty Subjects	Octreotide	Phase I	Intravenous
	28	Uterine fibroids	PROGENTA (CDB-4124)	Phase I/II	Intramuscular
	29	Acute Myelogenous Leukemia (AML)	AKN-028	Phase I/II	Oral / Tablets
	30	Idiopathic thrombocytopenic purpura	BMS-986004	Phase I/II	Intravenous
	31	Diffuse Large B-Cell Lymphoma (DLBCL)	Betalutin	Phase I/II	Intravenous
	32	Follicular lymphoma	Betalutin	Phase I/II	Intravenous
	33	Non-small-cell lung cancer		Phase I/II	Intravenous
	34	Diffuse Large B-Cell Lymphoma (DLBCL)	Obinutuzumab (RO5072759), Atezolizumab (RO5541267), Polatuzumab vedotin (RO5541077)	Phase I/II	Intravenous
	35	Biliary Cancer	Galactomannan derivative	Phase II	Oral / Tablets
	36	Asthma	QAW039	Phase II	Oral / Capsule
	37	Mantle Cell Lymphoma	PCI-32765	Phase II	Oral / Capsule
	38	Plaque Psoriasis	MT-1303	Phase II	Oral
	39	Endometrioza	Telapristone acetate	Phase II	Oral / Tablets
	40	Asthma	Dupilumab	Phase II	Subcutaneous
	41	Multiple Myeloma	Ixazomib	Phase II	Oral / Tablets
	42	Plaque Psoriasis	Toreforant	Phase II	Oral / Tablets
	43	Diffuse Large B-Cell Lymphoma (DLBCL)	MOR208	Phase II	Intravenous
44	Non-Hodgkin Lymphoma	Duvelisib (IPI-145)	Phase II	Oral / Tablets	
45	Diffuse Large B-Cell Lymphoma (DLBCL)	Selinexor (KPT-330)	Phase II	Oral / Tablets	
46	Acute Myelogenous Leukemia (AML)	Selinexor (KPT-330)	Phase II	Oral / Tablets	
47	Vasomotor symptoms in Post-Menopausal Women	Estetrol	Phase II	Oral / Capsule	
47	Acute Lymphoblastic Leukemia (ALL)	Selinexor (KPT-330)	Phase II	Oral / Tablets	
49	Multiple Myeloma	Panobinostat	Phase II	Oral / Capsule	

Date issue: June 2018

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



21230869/3/Q

Early Clinical Development Studies Experience

	Lp.	Indication	Active substance	Phase	Route of administration
	50	Myelodysplastic syndrome	Azacitidine	Phase II	Oral / Tablets
	51	Colorectal cancer	Trifluridine/tipiracil (TAs-102)	Phase II	Oral / Tablets
	52	Multiple Myeloma	Ibrutinib (PCI-32765)	Phase II	Oral
	53	Plaque Psoriasis	PF-06700841	Phase II	Oral

Date issue: June 2018

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



21230869/3/Q